Format

Send to

Choose Destination
Liver Transpl. 2015 Jul;21(7):881-8. doi: 10.1002/lt.24139.

High risk of delisting or death in liver transplant candidates following infections: Results from the North American Consortium for the Study of End-Stage Liver Disease.

Author information

1
Department of Medicine, University of Pennsylvania, Philadelphia, PA.
2
Department of Hepatology, Baylor University Medical Center, Dallas, TX.
3
Department of Medicine, Mayo Clinic School of Medicine, Rochester, MN.
4
Department of Medicine, University of Texas Health Science Center, Houston, TX.
5
Department of Medicine, University of Colorado, Denver, CO.
6
Department of Medicine, University of Toronto, Toronto, ON, Canada.
7
Department of Medicine, University of California, San Diego, CA.
8
Department of Medicine, School of Medicine, Yale University, New Haven, CT.
9
Department of Medicine, Emory University, Atlanta, GA.
10
Department of Family and Community Health Nursing and Biostatistics McGuire VA Medical Center, Virginia Commonwealth University, Richmond, VA.
11
Department ofMedicine, McGuire VA Medical Center, Virginia Commonwealth University, Richmond, VA.

Abstract

Because Model for End-Stage Liver Disease (MELD) scores at the time of liver transplantation (LT) increase nationwide, patients are at an increased risk for delisting by becoming too sick or dying while awaiting transplantation. We quantified the risk and defined the predictors of delisting or death in patients with cirrhosis hospitalized with an infection. North American Consortium for the Study of End-Stage Liver Disease (NACSELD) is a 15-center consortium of tertiary-care hepatology centers that prospectively enroll and collect data on infected patients with cirrhosis. Of the 413 patients evaluated, 136 were listed for LT. The listed patients' median age was 55.18 years, 58% were male, and 47% were hepatitis C virus infected, with a mean MELD score of 2303. At 6-month follow-up, 42% (57/136) of patients were delisted/died, 35% (47/136) underwent transplantation, and 24% (32/136) remained listed for transplant. The frequency and types of infection were similar among all 3 groups. MELD scores were highest in those who were delisted/died and were lowest in those remaining listed (25.07, 24.26, 17.59, respectively; P < 0.001). Those who were delisted or died, rather than those who underwent transplantation or were awaiting transplantation, had the highest proportion of 3 or 4 organ failures at hospitalization versus those transplanted or those continuing to await LT (38%, 11%, and 3%, respectively; P = 0.004). For those who were delisted or died, underwent transplantation, or were awaiting transplantation, organ failures were dominated by respiratory (41%, 17%, and 3%, respectively; P < 0.001) and circulatory failures (42%, 16%, and 3%, respectively; P < 0.001). LT-listed patients with end-stage liver disease and infection have a 42% risk of delisting/death within a 6-month period following an admission. The number of organ failures was highly predictive of the risk for delisting/death. Strategies focusing on prevention of infections and extrahepatic organ failure in listed patients with cirrhosis are required.

PMID:
25845966
DOI:
10.1002/lt.24139
[Indexed for MEDLINE]
Free full text

Supplemental Content

Full text links

Icon for Wiley
Loading ...
Support Center